Clinical trial
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
NCT00376883 · Nordic Myeloma Study Group, Other · Completed
Key facts
| NCT number | NCT00376883 |
|---|---|
| Title | Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month |
| Official title | The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis. |
| Lead sponsor | Nordic Myeloma Study Group, Other |
| Collaborators | Nordic Cancer Union |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | pamidronate |
| Enrollment | 500 |
| Start date | Jan 1, 2000 |
| Completion | Oct 1, 2006 |
| First posted | Sep 15, 2006 |
| Last update posted | Jan 4, 2007 |
| Countries | Denmark, Norway, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: